278 related articles for article (PubMed ID: 31652074)
21. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
[TBL] [Abstract][Full Text] [Related]
22. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
de Keizer B; van Aken MO; Feelders RA; de Herder WW; Kam BL; van Essen M; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):749-55. PubMed ID: 18210106
[TBL] [Abstract][Full Text] [Related]
23. Treatment with
Estorch M
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748
[No Abstract] [Full Text] [Related]
24. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
25. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of
Zhang J; Song Q; Cai L; Xie Y; Chen Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
[TBL] [Abstract][Full Text] [Related]
27. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.
Halperin DM; Dasari A; Yao JC
Future Oncol; 2016 Feb; 12(3):313-21. PubMed ID: 26759064
[TBL] [Abstract][Full Text] [Related]
28. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
29.
Strosberg JR; Caplin ME; Kunz PL; Ruszniewski PB; Bodei L; Hendifar A; Mittra E; Wolin EM; Yao JC; Pavel ME; Grande E; Van Cutsem E; Seregni E; Duarte H; Gericke G; Bartalotta A; Mariani MF; Demange A; Mutevelic S; Krenning EP;
Lancet Oncol; 2021 Dec; 22(12):1752-1763. PubMed ID: 34793718
[TBL] [Abstract][Full Text] [Related]
30.
Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
[TBL] [Abstract][Full Text] [Related]
31. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
Sowa-Staszczak A; Pach D; Kunikowska J; Krolicki L; Stefanska A; Tomaszuk M; Buziak-Bereza M; Mikolajczak R; Matyja M; Gilis-Januszewska A; Jabrocka-Hybel A; Trofimiuk M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(5):392-400. PubMed ID: 22069099
[TBL] [Abstract][Full Text] [Related]
33. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.
Paganelli G; Sansovini M; Ambrosetti A; Severi S; Monti M; Scarpi E; Donati C; Ianniello A; Matteucci F; Amadori D
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1845-51. PubMed ID: 24615468
[TBL] [Abstract][Full Text] [Related]
34. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.
Wild D; Fani M; Fischer R; Del Pozzo L; Kaul F; Krebs S; Fischer R; Rivier JE; Reubi JC; Maecke HR; Weber WA
J Nucl Med; 2014 Aug; 55(8):1248-52. PubMed ID: 24963127
[TBL] [Abstract][Full Text] [Related]
35. Lutetium-177 DOTATATE: A Practical Review.
Jia AY; Kashani R; Zaorsky NG; Spratt DE; Kiess AP; Michalski JM; Zoberi JE; Kim H; Baumann BC
Pract Radiat Oncol; 2022; 12(4):305-311. PubMed ID: 35717045
[TBL] [Abstract][Full Text] [Related]
36. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
37. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
39. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
40. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
Khan S; Krenning EP; van Essen M; Kam BL; Teunissen JJ; Kwekkeboom DJ
J Nucl Med; 2011 Sep; 52(9):1361-8. PubMed ID: 21795361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
